Published in Drug Discov Today on January 01, 2005
Recent advances in the chemistry and biology of naturally occurring antibiotics. Angew Chem Int Ed Engl (2009) 1.39
Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity. J Am Chem Soc (2014) 1.10
Drug discovery from natural products. J Ind Microbiol Biotechnol (2006) 1.07
Development of novel drugs from marine surface associated microorganisms. Mar Drugs (2010) 1.06
The evolving role of chemical synthesis in antibacterial drug discovery. Angew Chem Int Ed Engl (2014) 1.05
Structure-based discovery of antibacterial drugs. Nat Rev Microbiol (2010) 1.04
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob Agents Chemother (2008) 1.03
Importance of microbial natural products and the need to revitalize their discovery. J Ind Microbiol Biotechnol (2013) 1.03
Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci (2012) 1.00
Total synthesis of platensimycin and related natural products. J Am Chem Soc (2009) 0.99
Peptide design for antimicrobial and immunomodulatory applications. Biopolymers (2013) 0.99
The determinants of the antibiotic resistance process. Infect Drug Resist (2009) 0.98
Strategies and molecular tools to fight antimicrobial resistance: resistome, transcriptome, and antimicrobial peptides. Front Microbiol (2013) 0.98
Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-quinolinamines. Bioorg Med Chem (2006) 0.97
Bench-to-bedside review: Bacterial virulence and subversion of host defences. Crit Care (2008) 0.90
Prior antibacterial peptide-mediated inhibition of protein folding in bacteria mutes resistance enzymes. Antimicrob Agents Chemother (2006) 0.86
Synthesis and Biological Evaluation of Muraymycin Analogues Active against Anti-Drug-Resistant Bacteria. ACS Med Chem Lett (2010) 0.83
Expansion of Antibacterial Spectrum of Muraymycins toward Pseudomonas aeruginosa. ACS Med Chem Lett (2014) 0.82
Minimum requirements of hydrophobic and hydrophilic features in cationic peptide antibiotics (CPAs): pharmacophore generation and validation with cationic steroid antibiotics (CSAs). J Mol Model (2008) 0.81
In Vivo, In Vitro, and In Silico Characterization of Peptoids as Antimicrobial Agents. PLoS One (2016) 0.80
The relationship among antibiotic consumption, socioeconomic factors and climatic conditions. Can J Infect Dis Med Microbiol (2010) 0.80
Commentary: Toward a new focus in antibiotic and drug discovery from the Streptomyces arsenal. Front Microbiol (2015) 0.78
Novel approach to mapping of resistance mutations in whole genomes by using restriction enzyme modulation of transformation efficiency. Antimicrob Agents Chemother (2005) 0.78
Utilizing a dynamical description of IspH to aid in the development of novel antimicrobial drugs. PLoS Comput Biol (2013) 0.76
Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B. Fungal Biol Biotechnol (2015) 0.75
Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Chemother (2006) 1.51
Empirical antibacterial drug discovery--foundation in natural products. Biochem Pharmacol (2006) 1.32
Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J Biol Chem (2004) 1.17
Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr Opin Biotechnol (2003) 1.17
Antibacterial drug discovery--then, now and the genomics future. Biochem Pharmacol (2006) 1.03
Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa. J Nat Prod (2009) 0.96
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. Antimicrob Agents Chemother (2002) 0.90
Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics. Antimicrob Agents Chemother (2004) 0.90
Conserved fungal genes as potential targets for broad-spectrum antifungal drug discovery. Eukaryot Cell (2006) 0.87
Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347. J Am Chem Soc (2008) 0.86
Microbial genomics and novel antibiotic discovery: new technology to search for new drugs. Curr Pharm Des (2002) 0.84
Oxime derivatives of sordaricin as potent antifungal agents. Bioorg Med Chem Lett (2002) 0.80
Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials. Bioorg Med Chem Lett (2004) 0.79
Control and prevention of MRSA infections. Methods Mol Biol (2007) 0.79
Antibacterial evaluations of thiazomycin- a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. J Antibiot (Tokyo) (2007) 0.79
Sordaricin antifungal agents. Bioorg Med Chem Lett (2003) 0.76
Antibiotics and pharmacogenomics. Pharmacogenomics (2003) 0.76
Isolation and structure elucidation of thiazomycin- a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. J Antibiot (Tokyo) (2007) 0.76
Biaryl isoxazolinone antibacterial agents. Bioorg Med Chem Lett (2005) 0.76
Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. Bioorg Med Chem (2008) 0.76
Functional genomics of gram-positive microorganisms. J Bacteriol (2004) 0.75
Potential risk of probiotic usage. Expert Opin Drug Saf (2006) 0.75
What are we looking for in new antibacterials and how do we design it? Expert Opin Investig Drugs (2006) 0.75
Patent alert. IDrugs (2004) 0.75
Pharmacoeconomics of treatment with the newer anti-Gram-positive agents. Expert Opin Pharmacother (2006) 0.75